



## Curriculum Vitae

**Angel E. Alsina, M.D., FACS, FAASLD**  
Collaborative Professor of Surgery

812 S. Poinsettia Dr  
Tampa, FL 33609  
Telephone: (813) 663-5220, direct  
e-mail: [alsinaliverconsulting@gmail.com](mailto:alsinaliverconsulting@gmail.com)  
Website: [www.alsinaliverconsulting.com](http://www.alsinaliverconsulting.com)

Highly respected liver surgeon with 24 years of liver transplant experience at a tertiary care, 1,010 bed teaching hospital. Trained at the Harvard Department of Surgery, New England Deaconess Hospital in Hepato-Biliary Surgery and Liver Transplantation, and St. Elizabeth's Medical Center, in Boston, MA.

American Board of Surgery certified. Fellow of the American Association for the Study of Liver Diseases and Fellow of the American College of Surgeons. Collaborative Professor at the University of South Florida, Morsani College of Medicine.

Broad knowledge in various fields: general Surgery, liver surgery, transplantation, hepatology (hepatitis C, drug-induced injuries and liver disorders), and hepato-oncology (liver cancer). Directed liver transplantation and liver cancer programs for a total of 20 years.

Proven track record: His liver transplant program performed at the 96th percentile in long term outcomes, nationally, from 130 transplant programs. His patients had 38% lower risk of death than the average program. He also outperformed every higher volume program in patient survival. Evaluated over 5,000 new liver cancer patients.

Principal investigator and researcher in 27 pivotal trials of liver transplantation, acute liver failure, fatty liver, hepatitis C, and liver cancer. Published in topics of acute liver failure, liver cancer, liver transplantation, cirrhosis and portal hypertension, ethnic and ethical aspects of transplantation, and liver oncology. Expert CME teacher nationally with Simply Speaking Hepatitis panel, advisor, research mentor, and speaking experience nationally and internationally.

Experienced medico-legal expert witness and consultant in surgical complications, hepatology, liver transplantation, liver oncology (cancer), bile duct injuries, drug-induced liver injuries, Correctional Medicine in liver disorders and Hepatitis C treatment in inmates, life expectancy in liver disease, and disability for transplant surgeons.

Professional Practice: Tampa General Medical Group, Tampa, FL  
Multi-Organ Transplant Surgeon  
HepatoBiliary Surgery and Liver Transplantation: October 2011 to May 2020.  
Director Liver Cancer Program, Tampa General Hospital, 2007 to 2019

Multi-Organ Transplant Surgeon, LifeLink HealthCare Institute.  
July 1996 to October 2011

Director, Liver Transplantation, LifeLink HealthCare Institute/  
Tampa General Hospital 2007-2018  
Assoc. Director 2002-2006.  
Interim Director 1999-2001

Education:  
Fellowship:

New England Deaconess Hospital, Boston, MA, Harvard Department of Surgery;  
ASTS Approved Fellowship in Transplantation and Hepatobiliary Surgery July,  
1994 to June, 1996.

Hartford Hospital, Hartford, CT.  
Department of Surgery; Univ. of Connecticut School of Medicine,  
Clinical and Research Fellowship in Organ Transplantation.  
July 1989 - June, 1991.

Residency: St. Elizabeth's Medical Center of Boston, Boston, MA  
Surgery Residency. July, 1987 - June 1989, and July 1992 - June, 1994.  
Chief Surgical Resident. July, 1993 - June, 1994.

Nassau County Medical Center, East Meadow, NY  
Surgery Residency. July, 1991 - June, 1992.

Graduate: Ponce School of Medicine, Ponce, Puerto Rico  
Doctor in Medicine. 1983 - 1987.

Undergraduate: Boston College, Chestnut Hill, MA  
BS, Major in Biology. 1979 - 1983.

Academic Appointments Collaborative Professor of Surgery, University of South Florida Morsani College  
of Medicine, 2018

Affiliate Associate Professor of Surgery, University of South Florida Morsani  
College of Medicine, 2009

Affiliate Associate Professor of Medicine, University of Puerto Rico, Medical Sciences Campus, 2009

Affiliate Assistant Professor of Medicine, University of Puerto Rico, 2002.

Affiliate Assistant Professor of Surgery, University of South Florida College of Medicine, 1996.

Clinical Fellow in Surgery, Harvard Medical School, 1994.

Clinical Fellow in Surgery, Tufts University School of Medicine, 1988.

Hospital appointments: Tampa General Hospital, Active Staff, 1996 - present

Licensure: Florida - No. ME 0071238; 1996 to present.  
Puerto Rico-No. 14019; 2001-2013

Certifications: American Board of Surgery - 1995. Recertified 2005 and 2013

#### Clinical Practice Innovations

In 2019, I introduced robotic surgery capabilities at Tampa General Medical Group, the only surgeon qualified in the group.

I developed the Liver Cancer Program in 2010 and Sub Specialty clinic for hepatocellular carcinoma in 2012. Upgraded multi-disciplinary tumor conference, created program requirements for liver cancer program, expanded clinic, established chemotherapy treatments and obtained Tumor Board designation for liver cancer at the Cancer Committee and brought several clinical trials in hepatocellular carcinoma to my institution.

In 1999, I began a collaborative effort with the University of Puerto Rico and the Department of Health in Puerto Rico to assist with an undeserved population of liver transplant candidates that had limited access to life-saving treatments. This satellite clinic with the Division of Gastroenterology at UPR continued until 2012, at which point the local program opened.

Honors: At Ponce School of Medicine: Emergency Medicine, Internal Medicine, Surgery, Primary Care, Urology, Psychiatry, Microbiology, Medical Ethics, Clinical Medicine, Family and Community Medicine and Biostatistics.

Awards: Compassionate Doctor Award - 5 Year Honoree (2014, 2016, 2018). Vitals

Compassionate Doctor Award - 5 Year Honoree recognizes doctors with the highest scores in bedside manner for five consecutive years.

Compassionate Doctor Recognition (2010, 2011, 2012, 2013, 2014, 2015, 2016, 2018). Compassionate Doctor certification is granted to physicians who treat their patients with the utmost kindness. The honor is granted based on a physician's overall and bedside manner scores.

On-Time Doctor Award (2014, 2015, 2016, 2018). Vitals On-Time Promptness Award recognizes doctors with consistent high ratings for timeliness of appointments

Patients' Choice 5th Anniversary Award (2012, 2013, 2014, 2016, 2018)  
The Patients' Choice Award - 5 Year Honoree is a recognition granted only to those doctors whose ratings have reflected excellence in care for five years in a row. Only 1% of all doctors in the United States are bestowed this honor by their patients.

Patients' Choice Award (2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2018). Patients' Choice recognition reflects the difference a particular physician has made in the lives of his/her patients. The honor is bestowed to physicians who have received near perfect scores, as voted by patients

Castle Connolly Regional Top Doctors: 1st Edition. Tampa Bay Magazine: Top Doctors: 2018.

Top 10 Doctor - City (2014). Vitals awards Top 10 Doctor honors to those physicians within a certain specialty and geographic area who are consistently given top ratings by their patients.

Tampa Top Doctors 2020, *Tampa Magazine*

Ludwig J. Pyrtek, M.D. award for best manuscript in Hartford Hospital among resident and fellows, May, 1991. Alsina A, Schweizer R., Successful orthotopic porcine small bowel transplantation with low dose Cyclosporine in triple immunosuppressive therapy.

Chairman of the Board Award LifeLink Foundation, 2000.

American Liver Foundation, Gulf Coast Chapter Award 2005

#### Clinical Trials:

##### A. At LifeLink HealthCare Institute, as Co-Investigator:

1. Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure. #20-98-002, Fujisawa.

2. Open label study of Neoral as primary immunosuppressant in transplant patients who are unable to maintain satisfactory immunosuppression on Prograf. #OLN-452, Novartis.
3. A 6 day, open label, pharmacokinetic bioavailability evaluation of mycophenolic acid when switching from intravenous mycophenolate mofetil to oral mycophenolate mofetil in renal transplant recipients in the immediate post-op period. # MYLC 2734. Roche.
4. A double blind, comparative study of the effect of low dose levels of sirolimus versus azathioprine, administered concomitantly with standard immunosuppression therapy in renal allograft recipients. # 0468E1-301-US, Wyeth-Ayerst.
5. A phase III, randomized, double blind, placebo controlled, multicenter study of the efficacy of odulimomab (antiLFA) in preventing delayed graft function (DGF) of cadaveric renal allografts in patients not receiving biological induction immunosuppressive therapy. # AFO 12396. IMTIX.
6. A randomized, open label, pilot study of cyclosporine elimination in renal allograft recipients treated with sirolimus, cyclosporine and corticosteroids in the early post-operative period. # 0468 E1-212-US. Wyeth Ayerst.
7. A randomized, double blinded, double dummy, active-comparative controlled multi-center study of the efficiency and safety of Valgancyclovir (R0101-9070) vs oral gancyclovir for prevention of cytomegalovirus disease in high risk heart, liver and kidney allograft recipients.
8. An open label, prospective, randomized, multi-center, Phase II comparative trial of Thymoglobulin vs Simulect for the prevention of delayed graft function and acute allograft rejection in renal allograft recipients.
9. A randomized, open label, comparative evaluation of conversion from calcineurin inhibitors to Sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients. # 0468 H1-316-US. Wyeth-Ayerst.
10. A 1 year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of Certican™.(RAD 001) with Simulect® corticosteroids and optimized administration of Neoral® in de novo renal transplant recipients. CRAD001A2307. Novartis.
11. A prospective, randomized, open label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with Tacrolimus associated abnormal glucose metabolism to Neoral with C<sub>2</sub> monitoring. Novartis COLO 400 A US 06.
12. An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf + Rapamune + Corticosteroids Compared to Cyclosporine USF (Modified) + Rapamune + Corticosteroids in High Risk Renal Allograft Recipients

13. A prospective, randomized, open-label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with tacrolimus-associated abnormal glucose metabolism to Neoral<sup>®</sup> with C2 monitoring.
14. A Randomized, Multicenter, Comparative Trial of Prograf (Tacrolimus) in Combination With Rapamune (Sirolimus) or CellCept (Mycophenolate Mofetil) After Kidney Transplantation
15. Randomized, Double-Blind, Comparative Study of Two Doses of Mycophenolate or Azathioprine Each in Combination with Cyclosporine and Corticosteroids for the Prevention of Rejection in Recipients of their First Cadaveric Renal Allograft.
16. A phase IV, randomized, open-label, comparative, multicenter, study to assess the safety and efficacy of induction agents Alemtuzumab (Campath), Basiliximab (Simulect) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin) in combination with Tacrolimus (Prograf), Mycophenolate Mofetil (CellCept) and a rapid steroid withdrawal in renal transplant recipients.
17. An open label; prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration controlled CellCept<sup>®</sup> regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors.
18. A prospective, randomized, open-label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with tacrolimus-associated abnormal glucose metabolism to Neoral<sup>®</sup> with C2 monitoring
19. Reduction of PRA (Panel Reactive Antibody) in Sensitized Patients Awaiting Live-Donor Renal Transplantation. 2002-present
20. A phase IIB, randomized, multicenter, open-label, concentration controlled, safety study of ISA247 and Tacrolimus in de novo renal transplant patients
21. A Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Intravenous, Single Ascending Dose Study of the Safety, Pharmacokinetics, and Efficacy of YPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation
22. A one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral<sup>®</sup> and corticosteroids versus mycophenolate mofetil (MMF, CellCept<sup>®</sup>) combined with full-dose Neoral<sup>®</sup> and corticosteroids, in de novo adult renal transplant recipients
23. A Randomized, Open-Label Preference Study of Gengraft<sup>TM</sup> Compared to Neoral in Stable Solid-Organ Transplant Subjects
24. A Twelve-Month, Randomized, Multicenter, Open-Label Study to Investigate the Clinical Outcomes of Two Immunosuppressive Regimens of Myfortic with Short-Term Steroid Use or Free of Steroids Compared with a Regimen of Myfortic with Standard Steroids in De Novo Kidney Recipients Receiving Simulect and Neoral

25. A one-year, multicenter, open-label, randomized study to evaluate the safety and the efficacy of FTY720 combined with tacrolimus and steroids vs. MMF (Cellcept®) combined with tacrolimus and steroids, in de novo adult renal transplant recipients

26. A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients.

27. A Phase IIb, randomized, open label, comparative, multi-center study to assess the safety and efficiency of Prograf vs. modified release Tacrolimus (MR) with CellCept and should withdrawal in de Novo Liver Transplant recipients (20-05-001, Astellas Pharma US, Inc).

28. Belatacept evaluation of Nephro protection and efficiency of first line immunosuppression trial in extended criteria donors (Benefit-Ext). (IM103027, BMS.)

29. A Phase I /II multi-center, randomized, double blind, placebo-controlled, pilot trial to assess the effect of treatment of the recipient vein of polytetrafluoroethylene (PTFE) vascular access graft with two concentrations of E2F Decoy as compared to placebo on neointimal hyperplasia and the preservation of graft function in patients with chronic renal failure requiring dialysis. 2002-2004

#### As Principal Investigator

2003-2005

30. A randomized, open label, comparative evaluation of conversion from calcineurin inhibitor treatment to Sirolimus treatment vs. continued calcineurin inhibitor treatment in liver allograft recipients undergoing maintenance therapy. (Wyeth 0468H1-313-US)

31. A prospective, open label, multi-centers, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with Mycophenolate Mofetil and sirolimus in recipients of an orthotopic liver transplant. (Roche Liver STN-ML 18423) 2006-2008

32. A Randomized, double blind, double dummy study to assess the efficiency and safety of prophylactic use of Maribavir versus oral Gancyclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants. Maribavir/Protocol 1263-301 Viropharma, Inc.) 2007

33. Evaluation of Belatacept as first line immunosuppressant in de-novo liver transplant recipients (BMS, IM 103045) 2008

34. Everolimus Liver Trial: A 24 month, multicenter, open label, randomized, controlled study to evaluate the efficiency and safety of concentration-controlled everolimus to eliminate or reduce tacrolimus in de-novo liver transplant recipients ( RAD 001, Novartis) 2008

35. A phase 2, open label, multicenter, randomized trial to demonstrate the pharmacokinetics of LCP Tacro tablets once daily and Prograf capsules twice daily in adult de novo liver transplant patients. (LCP-Tacro 2018, LifeCycles Pharma) 2008

2009

36. A phase 2 randomized, multicenter, placebo-controlled, double-blind, parallel group study to evaluate the efficacy, safety and population pharmacokinetics of once-daily oral E5501 tablets used up to seven days in subjects with chronic liver diseases and thrombocytopenia prior to elective surgical procedures or diagnostic procedures (Eisai)

B. At Tampa General Medical Group, as Coinvestigator:

37. A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys R) and Ribavirin (Copegus –R) in Subjects Chronically Infected with Genotype 1 Hepatitis C Virus Following Liver Transplantation (Vertex, VX 11-950-117) 2011

38. A Non-Interventional, Prospective, Cohort Study of the Effectiveness, Safety, and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practice in the USA (Roche ML 279000)

39. A Phase 3, Safety and Efficacy Study of Short Duration boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic Hepatitis C Genotype 1 IL28B CC Patients (Merck 3034-040-00)

40. A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 2B Study to Compare the Efficacy and Safety of Quadruple Therapy ( VX-222, Telaprevir, Peginterferon-Alfa 2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subjects with Genotype 1 Chronic Hepatitis C with Compensated Cirrhosis. (Vertex VX 11-222-106)

41. Hi Q Quadraspheres Chemoembolization Trial in Hepatocellular Carcinoma

42. Optimal Boceprevir in community practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Educational Program

43. Vertex 116 An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved Sustained Viral Response With Prior Course of Interferon-Based Therapy

44. A randomized, open-label, multicenter, controlled study to assess the safety and efficacy of ELAD in subjects with acute alcoholic hepatitis. Vital Therapies. 2013.

45. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects with Compensated Liver Cirrhosis.

46. Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy using Rifaximin



47. A 5-year, longitudinal observational study of the natural history and management of patients with hepatocellular carcinoma. Target PharmaSolutions, TARGET-HCC. 2018

As Principal Investigator:

2011- 2020

47. Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery (Bayer ONC 2010-19)

48. A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS- Secondary to NASH (Gilead GS-US-321-0105)

49. A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2(LOXL), in Subjects with Cirrhosis Secondary to 6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2(LOXL), in Subjects with Advanced Liver Fibrosis but not Cirrhosis NASH (Gilead GS-US-321-0106)

50. A long term follow up registry of subjects who achieve a sustained virologic response to treatment in Gilead- sponsored trials in subjects with chronic hepatitis C infection. (Gilead GS-US-248-0122)

51. A long term follow up registry of subjects who did not achieve a sustained virologic response to treatment in Gilead- sponsored trials in subjects with chronic hepatitis C infection. (Gilead GS-US-248-0123)

52. A phase 2, multicenter, randomized, partially blind, dose ranging study to evaluate the efficacy and safety of VX-135 and Daclatasvir with or without ribavirin for 12 weeks in treatment-naïve adult subjects with genotypes 1, 2, or 3 chronic hepatitis C virus (Vertex 13-135-106)

53. Sorafenib adjuvant high risk liver transplants with HCC (ONC 2011-31)

54. Phase 2 Placebo-controlled, double-blind trial of dasatinib added to Gemcitabine for subjects with locally advanced pancreatic cancer. Otsuka 287-11-201

55. A randomized, open-label, multicenter, controlled study to assess the safety and efficacy of ELAD in subjects with acute alcoholic hepatitis. Vital Therapies. 2013.

56. A randomized, open-label, multicenter, controlled study to assess the safety and efficacy of ELAD in subjects with acute fulminant hepatic failure. Vital Therapies. 2013.

57. A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2(LOXL), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to NASH (Gilead GS-US-321-0105)

58. A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2(LOXL), in Subjects with Cirrhosis Secondary to NASH (Gilead GS-US-321-0106)

59. A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma, Eisai E7080-G000-304

60. A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib (BAY 73-4506) in patients with hepatocellular carcinoma (HCC) after sorafenib. Bayer 15982.

61. Topotinib second line therapy in hepatocellular carcinoma. EMD Serono 20095. 2016

62. A multicenter, single arm, Phase 1b/II study to evaluate the efficacy, safety, and PK of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma with Child Pugh class A liver function who have failed sorafenib. EMR 200095-005. 2016

63. A Phase 3 Multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab versus lenvatinib in first line therapy of participants with advanced hepatocellular carcinoma ( Merck Leap 002)

64. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants with Incurable/Non-metastatic hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012).

<https://clinicaltrials.gov/ct2/show/NCT04246177>

Lectures as Invited Speaker:

American College of Surgeons, 47<sup>th</sup> Annual Meeting, Puerto Rico Chapter, Overview of Pancreas Transplantation. San Juan, PR. 2/97.

3<sup>rd</sup> Annual Health Symposium, Organ Transplants, Gift of Life. Ponce, PR. 4/96. Overview of Organ Transplantation; Indications for Liver Transplantation; Brain Death.

3<sup>rd</sup> Annual Hepatobiliary/Pancreatic Surgery Symposium of American Society of Abdominal Surgeons. Nov 6, 1998. Tampa, FL. Organ Donation and Liver Transplantation.

American College of Surgeons, 49<sup>th</sup> Annual Meeting, Puerto Rico Chapter, San Juan, PR. 2/1999. Transplantation in the Next Millenium.

Donor Awareness Week. Organ Donation and Transplantation. Lakeland Regional Medical Center, Lakeland, FL. April 1999.

Latest Strategies and Management of Liver Diseases, 2000. Course Co-director and invited speaker. February 12, 13, 2000. St. Petersburg, FL. "Liver Transplantation".

Grand Rounds, Bon Secour-Venice Hospital. Liver Transplantation Update. April 2000.

American College of Surgeons, 51<sup>st</sup> Annual Meeting Puerto Rico Chapter "The Impact of the LifeLink Transplantation Institute/Tampa General Hospital Liver Transplant Program on Liver Transplantation in Puerto Rico" February 2001.

Grand Rounds University of Puerto Rico, Department of Medicine, "Pathophysiology of End Stage Liver Disease" and "Overview of Liver Transplantation" March 2001.

GI Symposium, University of South Florida April 2004. "Liver Transplantation, The Tampa Bay Experience".

"Post Transplant Hepatitis C", University of Puerto Rico, December 2003.

"Immunosuppression in Liver Transplantation". Auxilio Mutuo Hospital, San Juan, Puerto Rico, September 2003.

"Fulminant Hepatic Failure", University of Puerto Rico, December 2003.

"Liver Transplantation"; "Surgical Treatment of Portal Hypertension"; "Hepatocellular Carcinoma". Digestive Disease of the Caribbean, March 2003 San Juan, Puerto Rico.

"Liver Transplantation for Puerto Rico": The LifeLink-UPR experience". Presented to LifeLink Foundation Board of governors', November 2005.

Treatment and care of the patient with hepatic disease, joint symposium sponsored by Tampa General Hospital and The University of South Florida. February 2006. "Surgical Portosystemic Shunts".2009.

Distinguished Lecturer "Liver Transplantation" at the Annual Rubio Conference, at Univ of Puerto Rico, Department of Surgery, and at Dept of Medicine, San Juan Veterans Administration Hospital, 2009.

60<sup>th</sup> Annual Meeting ACS, PR Chapter Feb 2010. Bile duct injuries.

61<sup>st</sup> Annual Meeting ACS, PR Chapter, 2011, Hepatocellular Carcinoma in Puerto Rico.

63<sup>rd</sup> Annual Meeting ACS, PR Chapter, 2013. Transforming the Transplant Center with Research

67<sup>th</sup> Annual Meeting ACS, PR Chapter, 2017. Results of operations in cirrhotics performed by liver transplant surgeons

Annual Meeting of the Florida Society of the American College of Family Physicians:

Transplant for the family physician. July 2018, Champions gate, FL.

Annual Meeting of the Florida Society of the American College of Family Physicians: The NASH Epidemic. July 2019, Champions gate, FL.

Sociedad Mexicana de Oncologia: Importance of BCLC classification in unresectable hepatocellular carcinoma. July 15, 2020. Webinar

Sociedad Mexicana de Oncologia: Practical aspects in treatment decisions on hepatocellular carcinoma. July 23, 2020. Webinar

Other CME Lectures:

1. Veterans Administration Hospital, Tampa. Grand Rounds, Dec. 2013
2. TGH CME Dec 2013, Ft Myers
3. TGH CME 2012, Tampa
4. TGH CME 2010, Port Charlotte
5. Soc. Of Abdominal Surgeons, 2012 Tampa
7. Transplantation by the Bay, 2012 Tampa
8. Tampa Liver Forum 2012, 2013
9. FLASCO Executive Committee, 2011
10. Grand Rounds, Good Samaritan Medical Center, 2012
11. Simply Speaking Hepatitis National lecturer since 2011 in Hepatitis B, and C.

**Publications:**

Non-refereed journals:

1. Alsina A, Hull D, Bartus S, and Schweizer, R. Liver Transplantation for Acute Fulminant Hepatic Failure. Connecticut Medicine. 1992; 56: 235-239
2. Alsina A, Nagashima I, and Schweizer R. Orthotopic Porcine Small Bowel Transplantation with Low Dose Cyclosporine in Triple Immunosuppressive Therapy. Transplantation Proceedings 1992; 24: 1169-1173.
3. Nagashima I, Bergman L, Alsina A, and Schweizer R. Auxiliary Partial Liver Transplantation in Pigs with Acute Ischemic Liver Failure. Transplantation Proceedings 1993; 24(2): 1933-34.
4. Schweizer RT, Alsina AE, Rosson R, Bartus SA. Liver Transplantation for Metastatic Neuroendocrine Tumors. Transplantation Proceedings 1993; 24(2): 1933-4.
5. Kemmer N, Alsina A, Neff GW. Orthotopic liver transplantation in a multiethnic population: role of spatial accessibility. Transplant Proc. 2011;43(10):3780-2.

6. Kemmer N, Alsina A, Neff GW. Social determinants of orthotopic liver transplantation candidacy: role of patient-related factors. *Transplant Proc.* 2011; 43(10):3769-72.
7. Alsina A, Beharry A, Beharry N, Kemmer N, Franco E, Rojas H, Neff GW. Epidemiology of Hepatocellular Carcinoma in Florida – Part I: A Statewide Report. *Florida Public Health Review*, 2012; 9: 18-23
8. Ferro T, Alsina A, Rumbak M. Portopulmonary hypertension: An effect of vasomodulation and mortality post transplant. *Glob J Resp Care* 2014; 1:22-28.
9. A pilot study of high risk adjuvant sorafenib in high risk liver transplantation for hepatocellular carcinoma. Alsina A, Franco E, et al. *JSM Clin Oncol Res* 2016; 4:1049.

Refereed Journals:

1. Alsina A, Bartus S, Hull D, Rosson R, and Schweizer R: Liver Transplantation for Metastatic Neuroendocrine Tumor. *J. Clin Gastroenterol.* 1990; 12(5): 533-7.
2. Alsina A, Sziklas J, Rosenberg R, and Schweizer R: Value of 111-Indium Leukocyte Scans in Febrile Transplant
3. Savaria D, Townsend M, Alleman K, Alsina A, Olson N, Bartus S, Hull D, and Schweizer R. The Impact of Heart Donor and Recipient Cytomegalovirus Status on the Incidence of CMV Infection. *J Transplant Coordination* 1991; 1: 137-139.
4. Nagashima I, Bergman L, Alsina AE, Schweizer RT. Auxiliary heterotopic partial liver transplantation in pigs with acute ischemic liver failure. *Hepatogastroenterol* 1997;44:142631
5. Torres E., Guzman A., Vazquez M., Gregory F., Lozano H., Rivera C., Alsina A. Improving access to Liver Transplantation: The University of Puerto Rico Experience. *PRHSJ* 2004; 2:183-8.
6. Alsina A., Huang J., Bowers V., Leone J., Gonzalez H., Antunez I., Torres E., Potter T. Outcome of Liver Transplantation in a Hispanic Population: 100 Liver Transplants in Puerto Ricans. *PRHSJ* 2009; 28:301-306
7. Alsina A. Liver Transplantation for Hepatocellular Carcinoma. *Cancer Control* 2010; 17: 83-86
8. Le TV, Rumbak M, Liu SS, Alsina A, Van Loveren H, Agazzi S. Insertion of Intracranial Pressure Monitors in Fulminant Hepatic Failure Patients: Early Experience Using Recombinant Factor VII. *Neurosurgery* 2010; 66: 455-458
9. Toomey P, Golkar F, Hernandez J, Clark W, Luberic K, Alsina A, Rosemurgy A. Outcome after TIPS: A Bridge to Nowhere. *Am J Surg.* 2011 Nov;202(5):561-4. Epub 2011 Sep 23.

10. Clark W, Golkar F, Toomet P, Paul H, Marcadis A, Okpaleke C, Vice M, Hernandez J, Alsina A, Rosemurgy AS. Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts? *Am J Surg.* 2011 202(5):561-4.
  11. Lawindy S, Kurian T, Kim T, Manfag R, Armstrong P, Alsina A, Sheffield C, Sexton W, Spiess P. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. *BJU Int.* 2012 Apr 30.
  12. Rivera, MN, Jowsey S, Alsina A, Torres EA. Barriers to Liver Transplant in Puerto Ricans With Chronic Liver Disease. *PRHSJ.* 2012;4:199-204.
  13. Mathur A, Leone JP, Franco ES, Osman-Mohamed H, Rojas H, Kemmer N, Neff G, Rosemurgy AS, Alsina AE. Obesity Portends Increased Morbidity, Abbreviated Survival, and early recurrence Following Orthotopic Liver Transplantation for Hepatocellular Carcinoma. *HPB* 2013; 15: 504-10
  14. Neff G, Alsina A, Kemmer N, et al. Update on the management of cirrhosis - focus on cost effective preventative strategies. *Clinico Economics and Outcomes Research.* 2013;5: 143-152
  15. Trotter J, Alsina A, Grafals M. *Liver Transpl.* 2013;19(8):826-42. Early use of renal-sparing agents in liver transplantation: A closer look.
  16. Alsina A, Nakshabandi A, et al. Liver Transplantation for Hepatocellular Carcinoma in Puerto Ricans: Underutilization of a Curative Therapy. *PRHSJ.* 2014;33(4):170-6.
  17. Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, Alsina A. Non-Alcoholic Fatty Liver Disease Epidemic and its Implications for Liver Transplantation. *Transplantation.* 2013 Nov 27;96(10):860-2
- Alsina A, Nakshabandi A, Torres EA. Liver Transplantation for Hepatocellular Carcinoma in Puerto Ricans: Underutilization of a Curative Therapy. *P R Health Sci J.* 2014 Dec;33(4):170-6.
19. Naugler W, Alsina A, Frenette C, Rosssaro L, Sellers M. Building the Multidisciplinary Team for Management of Patients with Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol.* 2015 May;13(5):827-35
  20. Alsina A, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N. Can sorafenib extends survival of recurrent hepatocellular carcinoma following liver transplantation? *American Surgeon* 2014;80(7):680-4.
  21. Nakshabandi A, Franco E, Kemmer N, Alsina A Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma: A case report. *ACG Case Rep J.* 2016 Aug 17;3(4):e106
  22. Liver transplantation recipient with malignant transformation of hepatic adenoma. Leone P, Santos M, Finan J, Alsina A, Franco S. *Case Reports of Clin Pathol.* 2016; 3: 8-14.

23. Alsina A, Athienitis A, et al. Outcomes of elective abdominal surgeries in cirrhotic patients performed by liver transplant surgeons. Are they safer? *Am J Surg*. 2018 Sep;216(3):518-523
24. Alsina A, Apple R, Kemmer R., Orlowski D. The malleability of transplant criteria: At what costs? *Narrative Inquiry in Bioethics* 2019.
25. Alsina AE, Alsina AA, Athienitis A, Buggs J, Aslam S, Kemmer N. Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psycho-Social and Long Term Outcomes Study. *American Surgeon* 2018. 1;84(7):1197-1203.
26. DA, Teperman L, Ueda K, Silverman A, Chapman W, Alsina AE, Tyler C, Stevens DR. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. *Clin Pharmacol Drug Dev*. 2019 Jan 22. doi: 10.1002/cpdd.657
27. Alsina AE, Kudo M, Vogel A, Cheng AL, Tak W, Ryou B, Evans TR, Lopez C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn R. Subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. *Liver Cancer* ( # LIC-2019-9-19).
28. Alsina AE, Wind D, Kumar A, Rogers E, Buggs J, Bukkapatnam R, Sexton WJ. Outcomes in Renal Cell Carcinoma with IVC Thrombectomy: A Multiteam Analysis Between an NCI-Designated Cancer Center and a Quaternary Care Teaching Hospital. *Am Surg*. 2020;86(8):1005-1009

Abstracts:      National      [International](#)

[The Impact of Heart Donor and Recipient Cytomegalovirus Status on the Incidence of CMV Infection.](#) Savaria D, Townsend M, Alleman K, Alsina A, Olson N, Bartus S, Hull D, and Schweizer R, NATCO Annual Meeting, October, 1990, Halifax, Nova Scotia.

Preliminary Experience with Low Dose OKT3 in Renal and Liver Transplant Recipients. Schweizer R, Roper L, Alsina A, Hull D, and Bartus S. American College of Transplant Physicians Tenth Annual Meeting, May, 1991, Chicago, IL.

[Orthotopic Porcine Small Bowel Transplantation Using Low Dose Cyclosporine in Triple Immunosuppressive Therapy.](#) Alsina A, Nagashima I, and Schweizer R. International Symposium in Small Bowel Transplantation, October, 1991, London, Ontario.

Causes of Late Graft Failure in Cadaveric Kidney Transplant Recipients. Bergman L, Alsina A, Roper L, Bartus S, Hull D, and Schweizer R. Transplant Fellows Symposium, November, 1991, Chicago, IL.

Auxiliary Partial Liver Transplantation in Pigs with Acute Ischemic Liver Failure. Nagashima I, Bergman L, Alsina A, and Schweizer R. Liver Transplantation Symposium, 1992, Minneapolis, MN.

Decreased Cellular Immune Response in Hepatitis C Patients Awaiting Liver Transplantation. Huang J,, Lopez-Cepero M, Mayes J, Alsina A. American Society of Transplantation 2004.

Correlation of Cell Mediated Immune Response with Liver Allograft biopsy in Liver Transplant Recipients with Hepatitis C. Huang, J, Lopez-Cepero M, Mayes J, Alsina, A. American Society of Transplantation 2004.

Prophylactic Biliary Stent Placement after Orthotopic Liver Transplantation to Prevent Biliary Complications. Popli, R; Brady, P; Alsina, A Florida Gastroenterology Society October 2002.

Predictive Factors of Successful Liver Transplantation in a Population with Limited Access. Gregory, F, Vazquez M, Lozano H, Guzman A, Alsina.A. Digestive Disease Week 2004.

Analysis of the First 100 Liver Transplant Recipients from the Commonwealth of Puerto Rico: The LifeLink Healthcare Institute-University of Puerto Rico Experience. Alsina, A; Torres E; et al. DDW May 2006, Los Angeles, CA.

Single Center Comparative Study of the Efficacy of Valgancyclovir Vs Gancyclovir in High Risk CMV Mismatched Liver Transplantation. Alsina A, Bowers VD, Bruce D, Huang J, Leone JP, Nguyen T, Mendoza A, Silverman D. ASTS Winter Symposium, Marco Island, FL 2008.

Liver Transplantation in a minority Hispanic population. Torres E, Alsina A, et al. Asoc Latinoamericana Enfermedades de Hgado (ALEH), Margarita Island, Venezuela, July 2008

Induced Hypothermia May Improve Outcomes in Patients with High-Grade Encephalopathy Due to Fulminant Hepatic Failure. Franco E, Alsina A, et al. World Transplant Congress 2008.

Induced Hypothermia in high grade hepatic encephalopathy, The Florida Experience. Behrouz R, Hand HT, Malek AR, Alsina AE, Agazzi, Sloan A, van Loveren H, Rumbak M. Temperature Management Congress, Barcelona, Spain. 2008

Utility in Liver Transplantation for Fulminant Hepatic Failure: The Non organ for the Non eligible Liver Transplant recipient. Alsina A, Bowers V, Nguyen T, Leone J, Huang J, Ikram M, Kendall W. ASTS Winter Symposium, Marco Island, FL, 2009.

Liver Transplantation for hepatocellular carcinoma in well compensated cirrhotics. Alsina A, et al. AASLD 2010, Poster Presentation.

Barriers to Liver Transplant in Puerto Ricans With Chronic Liver Disease. Rivera, MN, Jowsey S, Alsina A, Torres EA. 12<sup>th</sup> International Symposium on health Disparities, Nashville, TN 2010

Outcome after TIPS: A Bridge to Nowhere. Toomey P, Golkar F, Hernandez J, Clark W, Luberic K, Alsina A, Rosemurgy A AHPBA Annual Meeting, 2011 Miami Beach, FL

Uncovering the Truth about Covered Stents: Is There a Difference Between Covered vs. Uncovered Stents with TIPS? Golkar F, Luberic K, Toomey P, Okpaleke M, Vice M, Hernandez J, Clark W, Ross J, Alsina A, Rosemurgy A. Association of VA Surgeons 35th Annual Meeting - April 2011, Irvine, California



Hepatic function in a liver transplant candidate with hepatocellular carcinoma: Impact on cancer recurrence and outcomes. Alsina A, Rojas H, Franco E, McGhee B, Leone J, Bowers V, Huang J, Mendoza A, Kemer N, Osman-Mohamed H, Neff G. AASLD 2011.

Impact of Drug Eluting Bead Chemoembolization on Survival and Recurrence of Hepatocellular Carcinoma (HCC) Post Liver Transplantation. Rojas H, Franco E, Davis C, Zweibel B, Brantley S, Neff G, Alsina A. AASLD 2011.

Assessment of Tumor Necrosis Following Chemoembolization for Hepatocellular Carcinoma in Liver Transplantation: Possible Benefit of Drug-eluting Beads, Alsina A, et al. ATC 2011.

Collateral Damage of Liver Transplantation in the Well Compensated Cirrhotic with Hepatocellular Carcinoma. Alsina A, Franco E, Leone J, Osman-Mohamed H, Huang J, Bowers V, Rojas H, McGhee B, Mendoza A, Kemmer N, Neff G. AASLD 2011.

Evaluation of Liver Transplantation Outcomes in Chronic Hepatitis C Genotype 1b versus 1a. Tong A, Silverman A, Franco E, Neff G, Alsina A. AASLD 2011.

Alsina A, Makris A. Differences in Hepatocellular Carcinoma Rates in Florida. American Statistical Association, Orlando 2012

Alsina A, Makris A, et al. Epidemiology of Hepatocellular Carcinoma in Florida. High Incidence Near Liver Transplant Centers. ASTS Winter Symposium, Miami, FL 2012

Mathur A, Leone J, Franco E, Osman-Mohamed H, Rojas H, Kemmer N, Neff G, Rosemurgy A, Alsina A. Obesity Portends an Increased Morbidity, Abbreviated Survival and Early Recurrence Following OLT for Hepatocellular Carcinoma AHPBA, Miami, FL 2012

Outcomes in patients with small hepatocellular carcinoma and chronic hepatitis C infection treated with RFA and antiviral therapy. Kemmer N, Alsina A, et al. AASLD 2012

Serum Albumin and Resource Utilization in Liver Transplantation, Kemmer N, Alsina A, et al. 2012 AASLD

Post liver transplant safety of rapid immunosuppression conversion prior to Daa/Peg/Riba therapy for recurrent HCV, Kemmer N, Alsina A, et al. 2012 AASLD

Outcomes in patients with cirrhosis using direct antiviral agents, ribavirin and pegylated interferon Kemmer N, Alsina A, et al. 2012 AASLD

Patient's Distance from a Liver Transplant Center Affects Outcomes Post Transplantation: Impact of Hepatitis C. Alsina A, Makris A, et al. AASLD 2012

Hepatic encephalopathy, physical functioning, and associated complications with compensated cirrhosis. Neff G, Kemmer N, Christian M, Ramirez M, Parkinson E, Cece, E, Cooper J, Mendoza A, Alsina A. ACG 2012 Annual Meeting.

Outcomes in length of Hospital stay in Cirrhotics admitted for Overt Hepatic Encephalopathy. Neff G, Kemmer N, Parkinson E, Cece, E, Christian M, Webster H, Cooper J, Houston S, Mendoza A, Gardner J, A, Alsina A, Bowers V. ACG 2012 Annual Meeting.

Readmission Rates and Maintenance of Overt Hepatic Encephalopathy. Neff G, Kemmer N, Cece E, Parkinson E, Christian M, Palamittam D, Cooper J, Mendoza A, Alsina A. ACG 2012 Annual Meeting.

Long Term Survival Following Overt Hepatic Encephalopathy. Neff G, Christian M, Ramirez M, Webster H, Galambo F, Parkinson E, Cece E, Cooper J, Alsina A, Mendoza A, Kemmer N. ACG 2012 Annual Meeting.

Malnutrition in Cirrhotics; Daily Calorie Counts and Nutritional Deficits Uncovered. Neff G, Kemmer N, Parkinson E, Cece E, Christian M, Galambo F, Cooper J, Mendoza A, Alsina A. ACG 2012 Annual Meeting.

Impact of Hispanic Ethnicity on Tacrolimus Dosing in Liver Transplant Patients. Silverman D, Alsina A, et al. American College of Pharmacy Annual Meeting 2013

Longer Distance to Liver Transplant Center Increases Mortality. Makris A, Zheng J, Alsina A, Huffer F, Devidas M.. 2013 Graduate Student and Postdoctoral Scholar Research Symposium, University of South Florida. March, 2013.

Longer Distance to Liver Transplant Center Increases Mortality. Makris A, Zheng J, Alsina A, Huffer F, Devidas 2013 USF Research Day

Survival and cancer recurrence in liver transplantation for hepatocellular carcinoma in the last decade. Is there progress? Alsina A, et al. AHPBA 2013

Improved Survival with Sorafenib and Multimodality Therapy in Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A Preliminary Report. Alsina A, et al. ASTS Winter 2013

Safety of Rapid immunosuppression Conversion Prior to Direct Antiviral Agents for Recurrent Hepatitis C Following Liver Transplantation. Alsina A, et al. ASTS Winter 2013

Predictors of outcomes in liver transplantation for hepatocellular carcinoma in the MELD era. Alsina A, et al. ASTS Winter 2013

Smoothing the likelihood function of distance effect in liver transplantation. Alsina A, Makris A, et al. AASLD 2013

High utilization of liver transplantation for hepatocellular carcinoma. Is it concerning? Alsina A, et al. AHPBA 2014.

Can sorafenib extends survival of recurrent hepatocellular carcinoma following liver transplantation. Alsina A, et al. Southeaster Surgical Congress, 2014.

A Socioeconomic Predictive Model for Access and Survival of Liver Transplant Patients: The Effects of Distance, Race, Insurance, Income, Work Status and Education. R Jacob, M Katzen, A Makris, A Alsina. USF Research Day 2014. Outstanding Undergraduate Poster

High utilization of liver transplantation for hepatocellular carcinoma. Is it concerning? K Vu, J Arrobas, E Franco, N Kemmer, A Valencia, A Makris, A Alsina. USF Research Day 2014.

Deleterious effect of body mass index and prior abdominal surgery on liver transplant complications. Alsina A, Zheng J, Makris A, Shim J, Franco S, Albers C, Kemmer N. AASLD 2014.

Everolimus safety profile in liver transplant recipients with a 3-year exposure in the H2304 Core and Extension Study. Saliba F, Rogiers X, Chapman W, Caicedo L, Alsina A, Teperman , Junge G, Rauer B, Dong G, DeSimone. ILTS 2014

The long term safety with everolimus based regimen in de novo liver transplant recipients: A 4 year results from the Extension of H2304 study. Saliba F, Rogiers X, Chapman W, Caicedo L, Alsina A, Teperman , Junge G, Rauer B, Dong G, DeSimone. WTC 2014.

Is There a Roll for Prophylactic Internal Biliary Stents With Orthotopic Liver Transplants to prevent Biliary Complications After Liver Transplant? Lipka S, Rodriguez A, Shiani A, Sethi S, Nehaul M, Snyder M, Chirumamilla, Valenzuela M, Lai A, Kumar A, Kemmer N, Brady P, and Alsina A. ACG 2015.

Vascular complications after trans-arterial chemoembolization in orthotopic liver transplant patients. Shiani A, Lipka S, Lai A, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Rodriguez A, Kumar A, Alsina A, Kemmer N, Brady P. ACG 2015

The impact of hepatitis C virus on biliary and vascular complications post-orthotopic liver transplantation. Rodriguez A, Shiani A, Lipka S, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Lai A, Lalama M, Kumar A, Alsina A, Kemmer N, Pinkas H, Brady P. ACG 2015

The incidence of biliary strictures after transarterial chemoembolization for hepatocellular carcinoma in orthotopic liver transplant patients. Shiani A, Rodriguez A, Lipka S, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Lai A, A, Kumar A, Alsina A, Kemmer N, Brady P. ACG 2015

Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma: A case report. Nakshabandi A, Franco E, Kemmer N, Alsina A. ACG 2015.

Red cell distribution width prior to liver transplantation is associated with post-transplant mortality. Caire T, Kumar A, Stravitz T, Franco E, Alsina A, Kemmer N. ILTS 2015

Tracking long term survival in hepatocellular carcinoma by a liver cancer multi-disciplinary team: The ultimate team. Alsina A, Makris A, Valencia A, Allison J, Claudio R, Johnstone M, Shim J, Franco E, Albers C, Kemmer N, Davis C, Zweibel B. ASTS 2015

A pilot study of high risk adjuvant sorafenib in high risk liver transplantation for hepatocellular carcinoma. Alsina A, Franco E, Makris A, Shim J, Allison R, Claudio R, Johnstone M, Barber K, Albers C, Kemmer N. AHPBA 2015

Single center experience with hypothermia in acute liver failure. Franco E, Alsina A. et.al. ASTS Winter 2016

Diagnostic accuracy of MRCP vs. ERCP findings in the post-orthotopic liver transplant population. Shiani A, Wolk B, Lipka S, Pinkas H, Kumar A, Alsina A, Kemmer N, Turner A, Brady P. DDW 2016.

A tissue-based study of VEGFR2 in human placenta: Association of mitochondrial enzymes pyruvate dehydrogenase component E2 (DLAT) and Sirtuin-4 (SIRT 4). Sinkey R, Okuka M, Stevens S, Steffensen T, Whiteman V, Alsina A, and Tsibris J. USF Research Day 2016.

Time on waiting list is a poor predictor of recurrence for hepatocellular carcinoma following liver transplantation: A Region 3 single study. Alsina A, Makris A, Lahoti M, Nakshabandi A, Parkinson E, Franco S, Albers C, Kemmer N. ASTS Winter 2016.

A failure of the past is not a determinant of future outcomes: Report of operations performed by liver transplant surgeons in patients with underlying cirrhosis. Alsina A, Athienitis A, et al. AASLD 2016. Presidential Poster of Distinction Award.

Utility of MELD –XI in congestive hepatopathy. Kemmer N, Alsina A, et al. AASLD 2016.

NAFLD in kidney transplant candidates. Kemmer N, Alsina A, et al. AASLD 2016.

Long term outcomes of hepatitis C liver transplantation in the direct acting antiviral era. Alsina A, Athienitis A, et al. AASLD 2017.

Hepatocellular carcinoma and hepatitis C transplants outperform other populations in the direct acting antiviral era. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2811312)

Is liver transplantation for acute liver failure the nemesis of transplantation? A two decade psycho-social and long term outcomes study. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2812392)

A two decade long term outcomes study of liver transplantation: Impact of specialized programs. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2816493)

Hepatocellular carcinoma and hepatitis C transplants outperform other populations in the direct acting antiviral era. **Alsina A**, Athienitis A, et al. USF Research Day 2018.

Is liver transplantation for acute liver failure the nemesis of transplantation? A two decade psycho-social and long term outcomes study. **Alsina AE**, Alsina AA, Athienitis A, et al. USF Research Day 2018

Is liver transplantation for acute liver failure the nemesis of transplantation? A two decade psycho-social and long term outcomes study. Alsina AE, Alsina AA, Athienitis A, et al. USF Undergraduate Research Colloquium 2018

A two decade long term outcomes study of liver transplantation: Impact of specialized programs. **Alsina A**, Athienitis A, et al. USF Research Day 2018.

### Committees:

Board of Directors, American Liver Foundation, Gulf Coast Chapter, Chair, Medical Advisory Committee, 2002-2008

Liver Transplant UNOS Regional Review Board-1999-2012

Lifeliink of Florida Advisory Board-1998-2011

Liver Transplant Medical Review Board-1996-2018

Board of Directors, Fundacion Ayuda Pacientes Hepaticos, Inc

Institutional Review Board, Univ. South Florida 2008-2012

Cancer Committee, Tampa General Hospital, 2010 to present

Transplant Council, Tampa General Hospital, 2010.

Scientific Review Committee, Tampa General Hospital, 2011-2012

Research Committee Tampa General Medical Group, 2013 –present

Executive Committee Institute for Advanced Organ Disease and Transplantation, Tampa General Hospital, 2017

USF Research Day, Poster Judge, 2015, 2016, 2018

### Organizing Role in Scientific Committees

Co-Director Florida Liver Forum 2011-2012

Co-Director Tampa Liver Symposium. DonCesar Resort, Sept 2017 and October 2019, St. Petersburg FL.

CME Director, Tampa Liver Symposium. DonCesar Resort, October 2019, St. Petersburg FL.

### Professional Societies:

Colegio de Medicos y Cirujanos de Puerto Rico 2003-present.

American College of Surgeons, Fellow, 1999.

American Society of Transplant Surgeons, 1999-present

American Association for Study of Liver Diseases, 1997-present. Fellow designation 2019

International Liver Transplant Society, 1997- present.

The Transplantation Society 2006- present.

American Hepatopancreatic Biliary Association 2013

### Other Scholarly Activities:

Task Forces: UNOS Liver Intestinal Committee Consensus Conference on Hepatocellular

carcinoma. 2008

Advisory Groups: Advisory Board member, Genzyme Corp.  
Expert Educator in Simply Speaking Hepatitis CME series.

Consultant Bayer Corp. Preceptorship on Hepatocellular Carcinoma given to SouthEastern sales force, June 2011.

Advisory Board Organ Recovery Systems 2012

Advisory Board Bayer Corporation, 2012. Developed a Multi-disciplinary Team model for treatment of Hepatocellular carcinoma

Advisory Board Eisai Corp, 2017-2019.

Advisory Board Vital Therapies 2018

Advisory Role in Research and Mentoring: I conducted Summer Research Programs with undergraduate students at University of Tampa and University of South Florida from 2012 to 2019.

2019: Undergraduate students (1)

2018: Undergraduate students (1)

2017: Undergraduate students (1)

2016: Undergraduate students (2); Masters (2); Medical students (1)

2015: Undergraduate students (4); Masters (2)

2014: Undergraduate Honors (2); Undergraduate (4); Masters (1)

2013: Undergraduate students (5); Masters (2)

2012: Undergraduate students (4); Masters (2)

2011: PhD's (2); RN (1)

2010: PhD's (1); DNP (1)

Updated 10/03/2020